The androxal is an oral medication for the treatment of prostate cancer and has become an important drug for the treatment of prostate cancer. The mechanism of action is to inhibit the effect of male androgens (such as testosterone) on prostate cancer cells, thereby slowing down or preventing tumor growth.
The growth of prostate cancer cells depends on the stimulation of male hormones, and Androxal inhibits the proliferation of prostate cancer cells by interfering with the binding of male hormones and their receptors. The androxal can not only treat early-stage prostate cancer but also treat metastatic prostate cancer.
The main indication of androxal is male hormone-sensitive prostate cancer, which means that prostate cancer cells are more sensitive to testosterone. This drug can be used in the following situations:
- Initial prostate cancer: Drug therapy before surgery or radiotherapy can be used as a single treatment or in combination with other treatment methods.
- Metastatic prostate cancer: Metastatic prostate cancer usually occurs after treatment, and this drug can be used to treat hormone therapy after drug-resistant metastasis. Androxalcan delays disease progression and improves survival.
- Patients with asymptomatic bone metastasis: androxal can be used to treat asymptomatic bone metastasis in prostate cancer patients.
However, androxal is not suitable for all prostate cancer patients. The drug is also ineffective for patients resistant to androgen therapy and is not recommended for the treatment of breast cancer, kidney cancer, and other types of cancer.
Overall, androxal is an important drug for treating prostate cancer, which can help patients alleviate symptoms, prolong survival, and improve quality of life.
